[go: up one dir, main page]

EA200201158A1 - Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов - Google Patents

Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов

Info

Publication number
EA200201158A1
EA200201158A1 EA200201158A EA200201158A EA200201158A1 EA 200201158 A1 EA200201158 A1 EA 200201158A1 EA 200201158 A EA200201158 A EA 200201158A EA 200201158 A EA200201158 A EA 200201158A EA 200201158 A1 EA200201158 A1 EA 200201158A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonists
application
cyclogexylamines
bicyclic
nmda
Prior art date
Application number
EA200201158A
Other languages
English (en)
Inventor
Шэм Шрайдхар Найкэм
Иэн Лесли Скотт
Брайан Алан Шерер
Лоренс Дейвид Вайз
Original Assignee
Уорнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уорнер-Ламберт Компани filed Critical Уорнер-Ламберт Компани
Publication of EA200201158A1 publication Critical patent/EA200201158A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны бициклзамещенные циклогексиламины формулы (I) и их фармацевтически приемлемые соли. Данные соединения являются антагонистами NMDA-рецептор-канальных комплексов (NMDA - N-метил-D-аспарагиновая кислота), полезными для лечения церебральных сосудистых расстройств, таких как, например, церебральная ишемия, остановка сердца, удар и болезнь Паркинсона. Заместители охарактеризованы в описании изобретения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200201158A 2000-05-31 2001-05-08 Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов EA200201158A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20824100P 2000-05-31 2000-05-31
PCT/US2001/014763 WO2001092239A1 (en) 2000-05-31 2001-05-08 Biciclic cyclohexylamines and their use as nmda receptor antogonists

Publications (1)

Publication Number Publication Date
EA200201158A1 true EA200201158A1 (ru) 2003-04-24

Family

ID=22773822

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201158A EA200201158A1 (ru) 2000-05-31 2001-05-08 Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов

Country Status (28)

Country Link
US (1) US6794402B2 (ru)
EP (1) EP1286975B1 (ru)
JP (1) JP2003535083A (ru)
KR (1) KR20030007797A (ru)
CN (1) CN1438996A (ru)
AP (1) AP2002002697A0 (ru)
AT (1) ATE302763T1 (ru)
AU (1) AU2001259618A1 (ru)
BG (1) BG107375A (ru)
BR (1) BR0111301A (ru)
CA (1) CA2409006A1 (ru)
DE (1) DE60112924T2 (ru)
DZ (1) DZ3361A1 (ru)
EA (1) EA200201158A1 (ru)
EE (1) EE200200667A (ru)
ES (1) ES2245985T3 (ru)
HR (1) HRP20021018A2 (ru)
HU (1) HUP0302323A2 (ru)
IL (1) IL153170A0 (ru)
IS (1) IS6625A (ru)
MA (1) MA26907A1 (ru)
MX (1) MXPA02011926A (ru)
NO (1) NO20025762L (ru)
OA (1) OA12275A (ru)
PL (1) PL359260A1 (ru)
SK (1) SK16632002A3 (ru)
WO (1) WO2001092239A1 (ru)
ZA (1) ZA200209325B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002749A (es) * 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
GB0116594D0 (en) 2001-07-06 2001-08-29 Cancer Res Ventures Ltd Therapeutic compounds
DE10210779A1 (de) 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
AU2003233244B2 (en) * 2002-06-07 2010-05-20 Cortical Pty Ltd Therapeutic molecules and methods-1
MXPA05006650A (es) 2002-12-20 2005-09-30 Cancer Rec Tech Ltd Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos.
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
JP5270943B2 (ja) * 2008-03-28 2013-08-21 大阪瓦斯株式会社 フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
AR080056A1 (es) * 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
KR20150000875A (ko) 2012-01-27 2015-01-05 내셔날 유니버시티 코포레이션 유니버시티 오브 토야마 세린 라세마제 저해제
CN105152966A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种叠氮化合物的制备方法
CN105001118A (zh) * 2015-07-20 2015-10-28 湖南华腾制药有限公司 一种含碘叠氮化合物的制备方法
CN105153020A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种芳香叠氮化合物的制备方法
CN105061254A (zh) * 2015-07-20 2015-11-18 湖南华腾制药有限公司 一种含溴叠氮化合物的合成方法
WO2018033525A1 (en) * 2016-08-16 2018-02-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonists or partial agonists of the histamine site of the nmda receptor for use in the treatment of central nervous system diseases
CN107043335A (zh) * 2017-05-31 2017-08-15 湖南华腾制药有限公司 一种2‑氟苯基叠氮化合物的制备方法
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
WO2025232878A1 (zh) * 2024-05-09 2025-11-13 苏州旺山旺水生物医药股份有限公司 一类含取代的苯基的胺类化合物、其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438055A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K Ring- und N-substituierte N-Benzyl-cycloalkylamine, ihre Salze mit physiologisch verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP0982026B1 (en) 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers

Also Published As

Publication number Publication date
ATE302763T1 (de) 2005-09-15
AU2001259618A1 (en) 2001-12-11
NO20025762D0 (no) 2002-11-29
HRP20021018A2 (en) 2004-02-29
ES2245985T3 (es) 2006-02-01
WO2001092239A1 (en) 2001-12-06
DE60112924T2 (de) 2006-03-16
KR20030007797A (ko) 2003-01-23
CN1438996A (zh) 2003-08-27
IS6625A (is) 2002-11-18
JP2003535083A (ja) 2003-11-25
ZA200209325B (en) 2004-02-16
PL359260A1 (en) 2004-08-23
US20030236252A1 (en) 2003-12-25
AP2002002697A0 (en) 2002-12-31
HUP0302323A2 (hu) 2003-10-28
EE200200667A (et) 2004-06-15
EP1286975B1 (en) 2005-08-24
US6794402B2 (en) 2004-09-21
EP1286975A1 (en) 2003-03-05
DE60112924D1 (de) 2005-09-29
BG107375A (bg) 2003-09-30
MXPA02011926A (es) 2003-04-22
SK16632002A3 (sk) 2003-08-05
OA12275A (en) 2003-12-11
CA2409006A1 (en) 2001-12-06
BR0111301A (pt) 2003-06-10
IL153170A0 (en) 2003-06-24
MA26907A1 (fr) 2004-12-20
NO20025762L (no) 2003-01-09
DZ3361A1 (fr) 2001-12-06

Similar Documents

Publication Publication Date Title
EA200201158A1 (ru) Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов
EA200200952A1 (ru) Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
EA200501274A1 (ru) Пиразолы и способы их получения и применения
BG66085B1 (bg) Фенилаланинови производни
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
CY1112628T1 (el) Νεοι αναστολεις κινασης
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
EP1369418A4 (en) Quinazoline derivatives
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
EA200500453A1 (ru) Имидазопиридины и способы их получения и применения
JO2371B1 (en) 4-phenyl-pyridine derivatives
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
WO2003048164A3 (en) Adenosine a2a receptor antagonists
EA200401301A1 (ru) Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора
EA200401114A2 (ru) Замещённые гидроксиэтиламины
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
EA200301276A1 (ru) Новые производные сульфоновых кислот
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
BR0111279A (pt) Derivados da ciclohexilamina como antagonistas para o receptor do nmda seletivo ao subtipo
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6